Source disclosure: February 16, 2026
Medrx Co., Ltd. [4586.T]
TOKYO, Feb 16 (Pulse News Wire) – Medrx CO.,LTD. (4586.T) announced today that patient registration for its Alto-101 Phase 2 Proof-of-Concept trial has been completed.
The trial, conducted in collaboration with U.S. biotech venture Alto Neuroscience, Inc., involves 83 patients across 13 clinical sites in the United States. The study evaluates the effect of Alto-101, a PDE4 inhibitor patch for treating schizophrenia, on brain wave measurements associated with cognitive dysfunction in schizophrenia.
This randomized, double-blind, placebo-controlled crossover design allows for within-subject comparisons, enhancing the sensitivity to detect treatment-related effects on EEG measures and cognitive function assessment metrics. Results from the trial are expected to inform future development strategies for Alto-101. There will be no impact on the current fiscal performance due to this completion.
AI-translated content. 🟢 Confidence: High See terms • Original filing